Denosumab can be a potential approach targeting the RANKL pathway in rheumatoid arthritis management

Primary tabs

NEWS
Denosumab can be a potential approach targeting the RANKL pathway in rheumatoid arthritis management

Rheumatoid arthritis (RA) is a chronic inflammatory disease marked by focal pathologic bone resorption and caused due to the excessive activity of osteoclasts (OC).

The receptor activator of nuclear factor kappa B ligand (RANKL) is significant for the proliferation, differentiation, and survival of OC. Denosumab (DMab) is a humanized monoclonal antibody,  which binds to RANKL with a high affinity and blocks its subsequent alliance with its receptor RANK on the surface of OC precursors.Chiu Y G and colleagues studied, the molecular and cellular mechanisms underlying the therapeutic applications of DMab, supplement recent highlights on pharmacology, efficacy, and safety of DMab, and the potential of DMab as a novel therapeutic option for the rheumatoid arthritis treatment.

The clinical results revealed that DMab is efficient in both systemic and articular bone loss in RA with finite side effects. Rheumatoid arthritis patients on corticosteroids and bisphosphonates displayed diminished bone erosion activity. The blend of DMab with a tumor necrosis factor inhibitor was not connected with the increased infection rate.

Overall, the data obtained from this study point-out that DMab, in combination with methotrexate and possibly other conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs), is an effective, safe and cost-effective choice for the treatment of RA.

Source:

Expert Opin Biol Ther.

Link to the source:

http://www.tandfonline.com/do.i/abs/10.1080/14712598.2017.1263614?journalCode=iebt20

The original title of the article:

Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis

Authors

Yahui Grace Chiu and Christopher T. Ritchlin

Log in or register to post comments